Article information
Abstract
Very limited data are available in the literature to elucidate the aetiology of invasive mould infections in Latin America. Here we report that Aspergillus species caused only half of such cases in a cohort study conducted over 21 months in a university hospital in Porto Alegre, Southern Brazil. Fusarium spp. were the second most prevalent moulds (20.7%), followed by Zygomycetes (13.8%). The importance of obtaining local epidemiological data for adequately guiding empirical antifungal therapy is reinforced.
Keywords:
Aspergillus
Fusarium
mold infections
epidemiology
zygomycosis
Full text is only available in PDF
References
[1.]
M.D. Richardson.
Changing patterns and trends in systemic fungal infections.
J Antimicrob Chemother, 56 (2005), pp. i5-i11
[2.]
K.A. Marr.
Invasive aspergillosis in allogenic stem cell transplant recipients: Changes in epidemiology and risk factors.
Blood, 100 (2002), pp. 66
[3.]
A.N. Malani, C.A. Kauffman.
Changing epidemiology of rare mould infections: implications for therapy.
Drugs, 67 (2007), pp. 1803-1812
[4.]
C. Lass-Flörl.
The changing face of epidemiology of invasive fungal disease in Europe.
Mycoses, 52 (2009), pp. 197-205
[5.]
D. Neofytos, D. Horn, E. Anaissie, et al.
Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Clin Infect Dis, 48 (2009), pp. 265-273
[6.]
O.A. Cornely.
Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections.
Infection, 36 (2008), pp. 296-313
[7.]
J. Perlroth, B. Choi, B. Spellberg.
Nosocomial fungal infections: epidemiology, diagnosis, and treatment.
Med Mycol, 45 (2007), pp. 321-346
[8.]
J.H. Van Burik, W. Leisenring, D. Myerson, et al.
The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients.
Medicine (Baltimore), 77 (1998), pp. 246-254
[9.]
G. Chamilos, M. Luna, R.E. Lewis, et al.
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).
Haematologica, 91 (2006), pp. 986-989
[10.]
L. Pagano, M. Caira, A. Nosari, et al.
Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study – Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.
Clin Infect Dis, 45 (2007), pp. 1161-1170
[11.]
B. De Pauw, T.J. Walsh, J.P. Donnelly, et al.
European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.
Clin Infect Dis, 46 (2008), pp. 1813-1821
[12.]
V.M. Carvalho-Dias, C.B. Sola, C.A. Cunha, S.E. Shimakura, R. Pasquini, F. Queiroz-Telles.
Invasive aspergillosis in hematopoietic stem cell transplant recipients: a retrospective analysis.
Braz J Infect Dis, 12 (2008), pp. 385-389
[13.]
M. Nucci, E. Anaissie.
Fusarium infections in immunocompromised patients.
Clin Microbiol Rev, 20 (2007), pp. 695-704
[14.]
A.S. Sekhon, A.A. Padhye, A.K. Garg, H. Ahmad, N. Moledina.
In vitro sensitivity of medically significant Fusarium species to various antimycotics.
Chemotherapy, 40 (1994), pp. 239-244
[15.]
A.L. Colombo, M. Nucci, B.J. Park, et al.
Epidemiology of Candidemia in Brazil: a Nationwide Sentinel Surveillance of Candidemia in Eleven Medical Centers.
J Clin Microbiol, 44 (2006), pp. 2816-2823
[16.]
A.L. Colombo.
Epidemiology and treatment of hematogenous candidiasis: a Brazilian perspective.
Braz J Infect Dis, 4 (2000), pp. 113-188
[17.]
V.R. Aquino, L.W. Lunardi, L.Z. Goldani, A.L. Barth.
Prevalence. Susceptibility Profile for Fluconazole and Risk Factors for Candidemia in a Tertiary Care Hospital in Southern Brazil.
Braz J Infect Dis, 9 (2005), pp. 411-418
[18.]
M.P.U. Sales, L.C. Severo, G.R. Geyer, J.J.P. Camargo.
Fungal infection in single and bilateral lung transplantation: report of 17 cases in 42 consecutive recipients.
South Am J Thorac Surg, 1 (1998), pp. 15-17
[19.]
A.C. Pasqualotto, D.W. Denning.
Post-operative aspergillosis.
Clin Microbiol Infect, 12 (2006), pp. 1060-1076
[20.]
D.L. Horn, J.A. Fishman, W.J. Steinbach, et al.
Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections.
Diagn Microbiol Infect Dis, 59 (2007), pp. 407-414
[21.]
C. Garcia-Vidal, A. Upton, K.A. Kirby, K.A. Marr.
Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation.
Clin Infect Dis, 47 (2008), pp. 1041-1050
[22.]
Nucci M, Cunha CA, Silla L et al. Multicenter Survey of Invasive Fungal Infections (IFI) in Patient with Hematologic Malignancies and Hematopoietic Stem Cell Transplant Recipients (HSCT) in Brazil (Abstract M-731). In: Abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, 2008.
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved
